Novartis' Entresto infringes on university patents, lawsuit claims
More than a year and a half after securing FDA approval for a blockbuster heart drug, Novartis is now going to court over it.
Novartis was served with a federal lawsuit earlier this week in the Northern District of California, alleging that its heart failure treatment Entresto infringes a patent jointly held by the University of Michigan and the University of South Florida related to “engineering crystals for the design of new drug compounds.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.